PFC Allbut9

@MichaelAlbertMD I'm actively working on solving the systemic issues professionally. But your expectation is insane to put on the average patient who either cannot afford routine care or has to wait 6-12 months for it.

🧬 The Ignition-Layer Is Real: $NWBO #DCVax, #UCLA’s DC-Vaccine Results, and Why $EIKN Systemic TLR-7/8 + $MRK #KEYTRUDA Closes the Circuit Dendritic-cell vaccines are built on a simple idea: the immune system cannot kill what it cannot recognize, and dendritic-cells are the professional teachers that show T-cells what to attack. Cold tumors fail because recognition alone is not enough. They fail at execution: weak interferon tone, weak chemokine gradients, and poor immune follow-through inside tissue. Three hard facts converge into one practical conclusion: A dendritic-cell platform supplies antigen instruction. A TLR-booster supplies innate ignition and interferon-architecture. Systemic delivery is the step that makes ignition consistent. 🧠 Two routes, one immune circuit: DCVax-L and DCVax-Direct DCVax-L is the systemic instruction route. DCVax-Direct is the intra-tumoral execution route: dendritic-cells are placed into the tumor-bed to take up antigen locally and then mature in-situ. Bosch’s NYAS deck describes DCVax-Direct as autologous, unloaded, partially-activated dendritic-cells with activation tightly controlled to preserve antigen uptake and enable subsequent maturation after injection, producing large-scale local cytokines linked to clinical effectiveness. Different routes. Same requirement: durable, tumor-specific T-cell immunity that executes in hostile tissue. 🧰 Bosch’s booster logic: DC output state is the bottleneck, and it is tunable Bosch’s deck makes the core claim explicit: patients whose dendritic-cells produce high levels of relevant cytokines have better tumor control and better survival. Then he names the lever: judicious combinations of DC-booster agents “supercharge” DCs prior to injection, and the first category listed is TLR-agonists (A, B, C). He also states the scale: production of TNF-α and IL-12p70 can rise by 1–2 orders of magnitude with additional booster agents. And he states the strategic hinge: “low cytokine producers” can be converted into high producers by adding booster agents. That is the blueprint: DC platforms win when the ignition layer forces DCs into a high-output execution state. 🧪 UCLA’s randomized phase-II trial: the DC-vaccine + TLR ignition layer works in humans, with numbers UCLA ran a randomized, multi-arm phase-II malignant glioma trial in which every patient received an autologous tumor-lysate–pulsed dendritic-cell vaccine called ATL-DC, with treatment completed 2010–2014 and survival follow-up continuing to the present. ATL-DC equivalence, briefly: ATL-DC is UCLA’s academic implementation of the same whole-tumor-lysate dendritic-cell vaccine chassis investors discuss as DCVax-L: autologous DCs loaded with autologous tumor lysate for broad antigen instruction. What the trial actually tested DC vaccine schedule: an initial series of 3 biweekly injections, then boosters at 4-month intervals. Randomized adjuvant arms: TLR-7/8 arm: resiquimod 0.2% gel applied days 0, 2, 4 after each DC injection (n=9). TLR-3 arm: poly-ICLC 20 mcg/kg IM at time of DC injection (n=9). Placebo (n=5). What the trial found Median OS: placebo 7.7 months, poly-ICLC 52.5 months, resiquimod 16.7 months. Median PFS: placebo 5.5 months, poly-ICLC 31.4 months, resiquimod 8.1 months. Durability: in IDH-mutant/Grade-III, all four ATL-DC + poly-ICLC patients were alive at cutoff with survivals >120 months (three) and >112 months (one). Then the paper nails the mechanism to the wall: both TLR arms lowered progression risk independent of grade, MGMT methylation, and recurrences, and risk of death was significantly lower in the poly-ICLC group. This is not a theory. This is the ignition layer functioning inside a human DC-vaccine framework. 🧭 Resiquimod: the TLR-7/8 signal is powerful, and topical delivery is the limiter The “resiquimod looks weaker” headline dies when you read the hazard ratios. In the GBM multivariate model, progression hazard vs placebo was: poly-ICLC: HR 0.02 (0.00–0.25), p=0.003 resiquimod: HR 0.03 (0.00–0.42), p=0.008 Resiquimod also slowed tumor growth kinetics: the tumor-volume increase rate was higher in placebo than resiquimod (p=0.022). That means the TLR-7/8 profile is one of Bosch’s A/B/C ignition profiles in real life: UCLA used it, measured it, and it worked. Topical application adds variability by design. The obvious upgrade is systemic, controlled TLR-7/8 dosing. 🧬 BDB001 / EIK1001: the systemic TLR-7/8 successor that activates endogenous dendritic-cells BDB001 (later EIK1001) is an intravenously administered TLR-7/8 agonist. It is not a DC vaccine. It is the ignition module. The BDB001-101 clinical record explicitly lists BDB001 (EIK1001) in combination with pembrolizumab, and lists Merck Sharp & Dohme LLC as the collaborator. 🤝 The $MRK collaboration came first, and it defines the circuit Before Eikon acquired the asset, Seven and Eight signed a clinical research collaboration with Merck (through a subsidiary) to explore BDB001 (TLR-7/8) in combination with Merck’s anti-PD-1 therapy KEYTRUDA in advanced solid tumors. This is the circuit by design: innate ignition (TLR-7/8) brake-release (anti-PD-1) 🏛 IPO and ticker: SEC-level confirmation that this ignition module is being commercialized Reuters reports Eikon filed for a U.S. IPO on Jan 9, 2026 and will list on Nasdaq under the symbol EIKN. Eikon’s S-1 itself is on the SEC site. That is public-market capitalization of a single claim: systemic TLR-7/8 ignition is a financeable module meant to be layered on checkpoint backbones. And EIK1001 is already being run in first-line NSCLC on the pembrolizumab + chemotherapy backbone: OncLive reports an interim ORR of 64% (95% CI 49–77) in 50 evaluable patients in TeLuRide-005 (NCT06246110), with no dose-limiting toxicities reported. ✅ One-line synthesis UCLA proves the DC-vaccine + TLR ignition layer works in humans, and the TLR-7/8 arm produces a massive, quantified progression-risk signal even with topical delivery. Bosch’s NYAS deck explains why: DC output state is the bottleneck and TLR profiles are the knob. Merck then anchors the circuit at the origin with a BDB001 + KEYTRUDA collaboration, and Eikon is now taking the systemic TLR-7/8 ignition module public as $EIKN. Informational only, not investment advice. Sources UCLA randomized phase-II malignant glioma trial (ATL-DC + resiquimod vs poly-ICLC vs placebo), Nature Communications 2024 — design (randomization, dosing, arms), outcomes, and multivariate hazard ratios. Bosch NYAS slide deck (DCVax-Direct + DC booster matrix) — DCVax-Direct description, “TLR agonists (A, B, C)” booster class, cytokine magnitude claim, and low-producer rescue concept. Seven and Eight BioPharmaceuticals press release (Merck collaboration for BDB001 + KEYTRUDA) — explicit collaboration statement. ClinicalTrials.gov record PDF for NCT03486301 (BDB001/EIK1001 ± pembrolizumab) — trial structure and Merck collaborator listing. Eikon IPO / ticker and filing date (Reuters) — IPO filing date and NASDAQ symbol “EIKN.” Eikon S-1 on SEC site — proposed listing under ticker “EIKN.” TeLuRide-005 interim NSCLC response reporting (OncLive) — interim ORR reported for EIK1001 + pembrolizumab + chemotherapy.